Clinical Trial Update: A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2, prospective, single-arm multicenter study evaluating JS004 in combination with toripalimab for unresectable or advanced renal cell carcinoma after prio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• JS004 (JS004)
• Toripalimab (Toripalimab)

Snippet

Sponsor: RenJi Hospital | Conditions: Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING